Asterias Biotherapeutics (AST) Downgraded to “Sell” at Zacks Investment Research

Zacks Investment Research lowered shares of Asterias Biotherapeutics (NYSEAMERICAN:AST) from a hold rating to a sell rating in a report released on Friday.

According to Zacks, “Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company’s technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. “

Separately, HC Wainwright set a $11.00 target price on shares of Asterias Biotherapeutics and gave the stock a buy rating in a research note on Monday, January 8th. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. Asterias Biotherapeutics presently has a consensus rating of Hold and a consensus price target of $8.94.

Asterias Biotherapeutics (NYSEAMERICAN:AST) traded up $0.03 during midday trading on Friday, reaching $2.40. 185,656 shares of the company’s stock traded hands, compared to its average volume of 219,174. Asterias Biotherapeutics has a one year low of $1.95 and a one year high of $5.00. The firm has a market capitalization of $129.96, a P/E ratio of -3.69 and a beta of 1.30.

Asterias Biotherapeutics (NYSEAMERICAN:AST) last released its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.15). Asterias Biotherapeutics had a negative net margin of 403.38% and a negative return on equity of 79.80%.

WARNING: This news story was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://sportsperspectives.com/2018/01/20/asterias-biotherapeutics-ast-downgraded-to-sell-at-zacks-investment-research.html.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Get a free copy of the Zacks research report on Asterias Biotherapeutics (AST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply